


Iriomoteolide-3a, a Cytotoxic 15-Membered Macrolide from a Marine Dinoflagellate *Amphidinium* Species

Keiko Oguchi,[†] Masashi Tsuda,*[‡] Rie Iwamoto,[†] Yumiko Okamoto,[†] Jun'ichi Kobayashi,[†] Eri Fukushi,[§] Jun Kawabata,[§] Tomoko Ozawa,^{||} Atsunori Masuda,^{||} Yoshiaki Kitaya,[⊥] and Kenji Omasa[#]

Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan, Center for Advanced Marine Core Research, Kochi University, Kochi 783-8502, Japan, Graduate School of Agriculture, Hokkaido University, Sapporo 060-8589, Japan, MARINE FARM, Yanmar Co. Ltd., Oita 873-0421, Japan, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka 599-8531, Japan, and Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan

mtsuda@kochi-u.ac.jp

Received October 6, 2007




A 15-membered macrolide, iriomoteolide-3a (**1**), with an allyl epoxide has been isolated from a marine benthic dinoflagellate *Amphidinium* sp. (strain HYA024), and the structure was assigned by detailed analyses of 2D NMR data. Relative and absolute configurations were elucidated on the basis of conformational studies of **1** and its acetoneide (**2**) and modified Mosher's method of **1**, respectively. Iriomoteolide-3a (**1**) and the acetoneide (**2**) exhibited potently cytotoxic activity against antitumor cells.

Marine dinoflagellates are known to produce bioactive secondary metabolites.¹ Members of *Amphidinium* are among the most abundant and diverse sand-dwelling benthic dinoflagellates worldwide,² and have been proven to be important sources of structurally unique polyketides.^{3,4} Macrolides such as amphidinolides,^{3,5} caribenolide-1,⁶ and amphidinolactones,⁷ isolated from symbiotic or free-swimming dinoflagellates *Amphidinium* sp., have various carbon chains as well as irregularly introduced

C₁ branches and oxygen substituents. More than half of amphidinolides possess odd-numbered lactone rings such as 15-, 17-, 19-, 25-, 27-, and 29-membered macrolides.^{3a}

Recently, we have screened numerous *Amphidinium* strains by using genetic analyses,⁸ cytotoxic screening, and metabolomics analyses, and found an *Amphidinium* strain, named HYA024, that produced unknown cytotoxic macrolides. Three new cytotoxic 20-membered macrolides, iriomoteolides-1a, -1b, and -1c, have been isolated from the strain.⁹ Further examination of the extract led to the isolation of a cytotoxic 15-membered macrolide, iriomoteolide-3a (**1**), with a novel carbon skeleton associated with an allyl epoxide moiety. Herein we describe the isolation and structure elucidation of **1**.



The *Amphidinium* strain, HYA024, was monoclonally separated from sea sand collected off Iriomote Island, Japan. The cultured algal cells (15.3 g, dry weight) obtained from 400 L of the medium were extracted with the MeOH/toluene solvent system. The toluene-soluble materials of the extract were

(2) (a) Dodge, J. D. *Marine Dinoflagellates of the British Isles*; Her Majesty's Stationary Office: London, UK, 1982; p 303. (b) Larsen, J. *Phycologia* **1988**, *27*, 366–377. (c) Larsen, J.; Patterson, D. J. *J. Nat. History* **1990**, *24*, 801–937. (d) Jørgensen, M. F.; Murray, S.; Daugbjerg, N. *J. Phycol.* **2004**, *40*, 351–365. (e) Murray, S.; Jørgensen, M. F.; Daugbjerg, N.; Rhodes, L. *J. Phycol.* **2004**, *40*, 366–382.

(3) (a) Kobayashi, J.; Tsuda, M. *Nat. Prod. Rep.* **2004**, *21*, 77–93. (b) Kobayashi, J.; Kubota, T. *J. Nat. Prod.* **2007**, *70*, 451–460.

(4) Recent reports of *Amphidinium* polyketides: (a) Huang, X.; Zhao, D.; Guo, Y.; Wu, H.; Lin, L.; Wang, Z.; Ding, J.; Lin, Y. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3117–3120. (b) Huang, X.; Zhao, D.; Guo, Y.; Wu, H.; Trivellone, E.; Cimino, G. *Tetrahedron Lett.* **2004**, *45*, 5501–5504. (c) Echigo, R.; Rhodes, L.; Oshima, Y.; Satake, M. *Harmful Algae* **2005**, *4*, 383–389. (d) Kubota, T.; Takahashi, A.; Tsuda, M.; Kobayashi, J. *Marine Drugs* **2005**, *3*, 113–118. (e) Morsy, N.; Matsuoka, S.; Houdai, T.; Matsumori, N.; Adachi, S.; Murata, M.; Iwashita, T.; Fujita, T. *Bioorg. Med. Chem.* **2006**, *14*, 6548–6554. (f) Washida, K.; Koyama, T.; Yamada, K.; Kita, M.; Uemura, D. *Tetrahedron Lett.* **2006**, *47*, 2521–2525. (g) Kubota, T.; Sakuma, Y.; Shimbo, K.; Tsuda, M.; Nakano, M.; Uozumi, Y.; Kobayashi, J. *Tetrahedron Lett.* **2006**, *47*, 4369–4371. (h) Kubota, T.; Endo, T.; Takahashi, Y.; Tsuda, M.; Kobayashi, J. *J. Antibiot.* **2006**, *59*, 512–516.

(5) (a) Oguchi, K.; Tsuda, M.; Iwamoto, R.; Okamoto, Y.; Endo, Y.; Kobayashi, J.; Ozawa, T.; Masuda, A. *J. Nat. Prod.* **2007**, *70*, 1676–1679. (b) Tsuda, M.; Kariya, Y.; Iwamoto, R.; Fukushi, E.; Kawabata, J.; Kobayashi, J. *Marine Drugs* **2005**, *3*, 1–8. (c) Kubota, T.; Sakuma, Y.; Tsuda, M.; Kobayashi, J. *Marine Drugs* **2004**, *2*, 83–87.

(6) Bauer, I.; Maranda, L.; Shimizu, Y.; Peterson, R. W.; Cornell, L.; Steiner, J. R.; Clardy, J. *J. Am. Chem. Soc.* **1994**, *116*, 2657–2658.

(7) (a) Takahashi, Y.; Kubota, K.; Kobayashi, J. *Heterocycles* **2007**, *72*, 567–572. (b) Takahashi, Y.; Kubota, K.; Kobayashi, J. *J. Antibiot.* **2007**, *60*, 376–379.

(8) Iwamoto, R.; Kobayashi, J.; Horiguchi, T.; Tsuda, M. *Phycologia* **2005**, *44* (Supplement), 104.

(9) (a) Tsuda, M.; Oguchi, K.; Iwamoto, R.; Okamoto, Y.; Kobayashi, J.; Fukushi, E.; Kawabata, J.; Ozawa, T.; Masuda, A.; Kitaya, Y.; Omasa, K. *J. Org. Chem.* **2007**, *72*, 4469–4474. (b) Tsuda, M.; Oguchi, K.; Iwamoto, R.; Okamoto, Y.; Fukushi, E.; Kawabata, J.; Ozawa, T.; Masuda, A. *J. Nat. Prod.* **2007**, *70*, 1661–1663.

* Address correspondence to this author.

[†] Graduate School of Pharmaceutical Sciences, Hokkaido University.

[‡] Kochi University.

[§] Graduate School of Agriculture, Hokkaido University.

^{||} Yanmar Co Ltd.

[⊥] Osaka Prefecture University.

[#] The University of Tokyo.

(1) Blunt, J. W.; Copp, B. R.; Hu, W.-P.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2007**, *24*, 31–86 and earlier reports in the series.




FIGURE 1. Selected 2D NMR correlations for iriomoteolide-3a (1).

subjected to SiO_2 gel, C_{18} , and $\text{NH}_2\text{-SiO}_2$ columns followed by C_{18} HPLC to afford iriomoteolide-3a (1, 0.015%), together with a known macrolide, iriomoteolide-1b.^{9b} Iriomoteolides-1a^{9a} and -1c^{9b} were obtained from a less-polar fraction of the SiO_2 gel column.

Iriomoteolide-3a (1, $[\alpha]_D^{25} +24$ (c 0.18, CHCl_3)) showed pseudomolecular ion peaks at m/z 457 ($M + \text{Na}$)⁺ and 469 ($M + ^{35}\text{Cl}$)⁻ in the positive- and negative-mode ESIMS spectra, respectively. The molecular formula, $\text{C}_{25}\text{H}_{38}\text{O}_6$, of 1 was established by HRESIMS data [m/z 457.2566 ($M + \text{Na}$)⁺, $\Delta +0.0$ mmu]. ^1H and ^{13}C NMR data (Table S1, Supporting Information) in CDCl_3 assigned by using the HMQC spectrum disclosed the presence of a total of 25 carbon signals due to an ester carbonyl, eight sp^2 methines, eight sp^3 methines including six oxygenated ones, five sp^3 methylenes, and three methyls. Because five out of seven unsaturation degrees were accounted for, 1 was inferred to possess two rings in the molecule.

Detailed analyses of ^1H - ^1H COSY and TOCSY spectra in CDCl_3 revealed a spin system from H_2 -2 to H_3 -23, H_3 -24, and H_3 -25 (Figure 1). Three disubstituted double bonds at C-5, C-9, and C-18 were indicated to possess *E*-geometries from $J(\text{H-5}/\text{H-6})$ (16.3 Hz), $J(\text{H-9}/\text{H-10})$ (15.5 Hz), and $J(\text{H-18}/\text{H-19})$ values (15.5 Hz), while *E*-geometry for the double bond at C-21 was deduced from the ^{13}C chemical shift for C-23 (δ_c 17.8)¹⁰ as well as NOESY correlations for H_3 -20/H-22 and H_3 -21/H-23. The presence of a trans epoxide at C-11 was suggested by $J(\text{C-11}/\text{H-11})$ and $J(\text{H-11}/\text{H-12})$ values (180 and 2.3 Hz, respectively). The phase-sensitive HMBC¹¹ spectrum showed correlations from H_2 -2 and H_3 -14 to the ester carbonyl carbon (C-1), suggesting that C-14 was involved in an ester linkage with C-1. Thus, the planar structure of iriomoteolide-3a was concluded to be 1 possessing a 15-membered macrolactone ring.

The relative configuration of 1 was deduced from bond-rotation analyses based on ^1H - ^1H coupling constants and NOESY data in CDCl_3 . For the C-1-C-6 portion (Figure 2), ^1H - ^1H coupling constants suggested anti for H_2 -2b/H-3 (7.8 Hz), H_3 -3/H-4b (8.9 Hz), and H_4 -4a/H-5 (10.0 Hz) and gauche relationships for H_2 -2a/H-3 (2.4 Hz), H_3 -3/H-4a (4.0 Hz), and H_4 -4b/H-5 (4.0 Hz).¹² Since NOESY correlations were observed for H_2 -2a/H-5, H_3 -3/H-6, H_4 -4a/H-6, and H_2 -4/H-24, the conformation for the C-1-C-6 portion was assigned as shown in Figure 2.

For the C-9-C-19 portion (Figure 3a), NOESY correlations for H_9 -9/H-11 and H_9 -10/H-12 and the $J(\text{H-10}/\text{H-11})$ value (9.8 Hz) indicated an anti relationship for H_9 -10-H-11. The relative




FIGURE 2. Relative stereochemistry for the C-1-C-6 portion in iriomoteolide-3a (1).




FIGURE 3. (a) Relative stereochemistry for the C-9-C-19 portion and rotations for (b) C-12-C-13 and (c) C-13-C-14 bonds in iriomoteolide-3a (1).

configuration for C-12-C-14 as well as orientation of the H_9 -10-epoxide oxygen atom were elucidated on the basis of the H_9 -based configuration analysis¹³ as follows. For the C-12-C-13 and C-13-C-14 bonds (Figures 3b and 3c), anti for H_9 -12-H-13b and H_9 -13b-H-14 and gauche relationships for H_9 -12-H-13a and H_9 -13a-H-14 were inferred by $J(\text{H-12}/\text{H-13a})$ (2.3 Hz), $J(\text{H-12}/\text{H-13b})$ (9.8 Hz), $J(\text{H-13a}/\text{H-14})$ (2.3 Hz), and $J(\text{H-13b}/\text{H-14})$ values (10.4 Hz) and NOESY correlation for H_9 -12/H-14. Both gauche relationships for H_9 -13a-H-14 and H_9 -13b-H-14 were deduced from relatively large negative values for $^2J(\text{C-12}/\text{H-13a})$ and $^2J(\text{C-12}/\text{H-13b})$ (both -6 Hz), which were estimated from the intensities¹⁴ of H_9 -13a-C-11 and H_9 -13b-C-11 cross-peaks in the phase-sensitive HMBC spectrum. The $^2J(\text{C-14}/\text{H-13a})$ (0 Hz) and $^2J(\text{C-14}/\text{H-13b})$ (-6 Hz) values were attributed to the anti and gauche relationships for H_9 -13a-14-O and H_9 -13b-14-O, respectively. Considering NOESY

(10) ^{13}C chemical shifts of terminal olefinic methyl groups were approximately δ 13 and 18 for *Z*- and *E*-geometries, respectively: Kalinowski, H.-O.; Berger, S.; Braun, S. In *Carbon-13 NMR Spectroscopy*; John Wiley & Sons: Chichester, UK, 1988; p 244.

(11) Zhu, G.; Live, D.; Bax, A. *J. Am. Chem. Soc.* **1994**, *116*, 8370-8371.

(12) a and b denote low- and high-field resonances, respectively, of geminal pairs for C-2, C-4, C-13, and C-16.

(13) (a) Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. *J. Org. Chem.* **1999**, *64*, 866-876. (b) Hansen, P. E. *Prog. NMR Spectrosc.* **1981**, *14*, 175-296.

(14) $^2J(\text{C}/\text{H})$ values were obtained by the equation $[J_{\text{anti}}/J_{\text{gauche}}] = \sin^2(\pi^2 J(\text{C}/\text{H})/\Delta) \sin^2(\pi^2 J(\text{C}/\text{H})/\Delta)$ ¹⁴ supposing $J(\text{C-21}/\text{H-23})$ as 7 Hz: Kalinowski, H.-O.; Berger, S.; Braun, S. In *Carbon-13 NMR Spectroscopy*; John Wiley & Sons: Chichester, UK, 1988; p 533.




FIGURE 4. Relative stereochemistry for the C-4–C-11 portion in the 7,8-*O*-isopropylidene derivative (**2**) of iriomoteolide-3a (**1**).

correlations for H-11–H-13b, H-12–H-14, and H-13a–H-15, it was indicated that the epoxide oxygen atom was oriented to the outside of the macrolactone ring. NOESY correlations for H-13a–H-15 and H-14–H-16b and the J (H-14, H-15) value (3.4 Hz) were suggestive of the three configuration for C-14–C-15. The 1,3-syn relation for C-15–C-17 was elucidated by J (H-15–H-16a), J (H-15–H-16b), J (H-16a–H-17), and J (H-16b–H-17) values (10.0, 3.6, 4.0, and 10.7 Hz, respectively) and NOESY correlations for H-14–H-16b, H-16b–H-18, and H-16–H-25.

The relative configuration for the C-6–C-9 portion for **1** was not determined, because H-7 (δ_{H} 3.965) and H-8 (δ_{H} 3.955) overlapped. Iriomoteolide-3a (**1**) was converted into the 7,8-*O*-isopropylidene derivative (**2**) by treatment with 2,2-dimethoxypropane and pyridinium *p*-toluenesulfonate. Two acetonide methyl signals at δ_{H} 1.44 (H₃-27) and 1.42 (H₃-26) showed NOESY correlations to H-7 (δ_{H} 4.02) and H-8 (δ_{H} 3.93), respectively, thus suggesting the 7,8-*trans* configuration (Figure 4). The relatively large J (H-6–H-7), J (H-7–H-8), and J (H-8–H-9) values (all 8.6 Hz) of **2** were indicative of anti relations for H-6–H-7, H-7–H-8, and H-8–H-9. The signal patterns for H-7 and H-8 of **1** agreed with those simulated as 8.6 Hz for J (H-6–H-7), J (H-7–H-8), and J (H-8–H-9) values using the NMR-PEAK.exe program by Nakamura¹⁵ (see Figure S13, Supporting Information), indicating anti relationships for H-6–H-7, H-7–H-8, and H-8–H-9 in **1**. Considering the conformations shown in Figures 2–4, the relative configurations of the eight chiral centers in **1** were proposed.

Elucidation of the absolute configuration for **1** was examined by application of modified Mosher's method.¹⁶ Treatment of **1** with (*R*)-(-)- and (*S*)-(+)-2-methoxy-2-trifluoro-2-phenylacetyl chloride (MTPACl) gave 7,8,15-tris-(*S*)- and (*R*)-MTPA esters (**3a** and **3b**, respectively) of **1**. Each of the ¹H NMR data for **3a** and **3b** were assigned by analyses of the ¹H–¹H COSY and TOCSY spectra, and chemical shifts differences ($\Delta\delta = \delta_{\text{S}} - \delta_{\text{R}}$) were shown in Figure 5. $\Delta\delta$ Values for H₂-16, H-17, H-18, and H₃-25 showed negative signs, while positive signs were observed for H-12, H₂-13, and H-14, thus suggesting that C-15 possessed *S*-configuration. Positive $\Delta\delta$ values for H-7 (+0.01) and H-8 (+0.03) corresponded to a typical $\Delta\delta$ pattern for diesters of *S,S*-1,2-diol with chiral anisotropic reagents reported by Riguera and co-workers.¹⁷ Therefore, the absolute configurations of **1** were assigned as 3*S*, 7*S*, 8*S*, 12*S*, 13*S*, 14*S*, 15*S*, and 17*R*.

(15) <http://nakamura-2.ces.hokudai.ac.jp/NakamuraXnmrnmr.html>

(16) Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092–4095.

(17) Seco, J. M.; Martino, M.; Quiñó, E.; Riguera, R. *Org. Lett.* **2000**, *2*, 3261–3264.




FIGURE 5. $\Delta\delta$ values [$\Delta\delta$ (in ppm) = $\delta_{\text{S}} - \delta_{\text{R}}$] obtained from 7,8,15-tris-(*S*)- and (*R*)-MTPA esters (**3a** and **3b**, respectively) of iriomoteolide-3a (**1**).

Iriomoteolide-3a (**1**) is a new 15-membered macrocyclic¹⁸ having an allyl epoxide, three hydroxyl groups, and two methyl branches. Although two classes of 15-membered macrolides such as amphidinolides *J*(*S*)¹⁹ and *O*(*P*)²⁰ had been isolated from the symbiotic dinoflagellate *Amphidinium* species, the carbon chain length and C₁- and oxygen-substituted positions for **1** are quite different from those of these known 15-membered macrolides. Naturally occurring macrolides generally possess an even-numbered lactone ring, since these macrolides may be generated through lactonization of a successive polyketide chain, and the oxygenated carbons derived from the C-1 carbonyl of acetates or propionates are involved in an ester linkage. In the previous biosynthetic studies of amphidinolides,²¹ however, the incorporation patterns revealed that they may be generated through non-successive polyketide including isolated C₁ units derived from C-2 of acetates, and the oxygenated carbons involved in an ester linkage are derived not only from the C-1 carbonyl but also the C-2 methyl of acetates. These biosynthetic features of *Amphidinium* macrolides may explain the generation of the odd-numbered lactone ring for **1**.

Our preliminary *in vitro* screening on antitumor and antiviral activities showed that iriomoteolide-3a (**1**) and its 7,8-*O*-isopropylidene derivative (**2**) exhibited potent cytotoxicity against human B lymphocyte DG-75 (IC₅₀: 0.08 and 0.02 $\mu\text{g/mL}$, respectively) and Raji cells (IC₅₀: 0.05 and 0.02 $\mu\text{g/mL}$, respectively), the latter of which was infected with Epstein–Barr virus (EBV). Further investigations on their biological activities are now in progress.

Experimental Section

Isolation. Cultivation and extraction were described previously.⁹ The toluene-soluble fractions (2 g) obtained from the harvested HYA024 cells (15.3 g, from 400 L of culture) were subjected to SiO₂ column chromatography (40 × 200 mm), using a stepwise

(18) Leigolide is a 15-membered macrocyclic lactone containing a lactam group in the macrocyclic ring: Klein, D.; Brackman, J.-C.; Daloz, D.; Hoffmann, E.; Demoulin, V. *Tetrahedron Lett.* **1996**, *37*, 7519–7520.

(19) (a) Kobayashi, J.; Sato, M.; Ishibashi, M. *J. Org. Chem.* **1993**, *58*, 2645–2646. (b) Ishibashi, M.; Takahashi, M.; Kobayashi, J. *Tetrahedron* **1997**, *53*, 7827–7832.

(20) Ishibashi, M.; Takahashi, M.; Kobayashi, J. *J. Org. Chem.* **1995**, *60*, 6062–6066.

(21) (a) Kobayashi, J.; Takahashi, M.; Ishibashi, M. *J. Chem. Soc., Chem. Commun.* **1995**, 1639–1640. (b) Sato, M.; Shimbo, M.; Tsuda, M.; Kobayashi, J. *Tetrahedron Lett.* **2000**, *41*, 503–506. (c) Kobayashi, J.; Kubota, T.; Endo, T.; Tsuda, M. *J. Org. Chem.* **2001**, *66*, 134–142. (d) Kubota, T.; Tsuda, M.; Kobayashi, J. *Tetrahedron* **2001**, *57*, 5975–5977. (e) Tsuda, M.; Kubota, T.; Sakuma, Y.; Kobayashi, J. *Chem. Pharm. Bull.* **2001**, *49*, 1366–1367. (f) Tsuda, M.; Izui, K.; Sato, M.; Kobayashi, J. *Chem. Pharm. Bull.* **2002**, *50*, 976–977. (g) Tsuda, M.; Izui, N.; Shimbo, K.; Sato, M.; Fukushi, E.; Kawabata, J.; Katsumata, K.; Horiguchi, T.; Kobayashi, J. *J. Org. Chem.* **2003**, *68*, 5339–5345. (h) Tsuda, M.; Izui, N.; Shimbo, K.; Sato, M.; Fukushi, E.; Kawabata, J.; Kobayashi, J. *J. Org. Chem.* **2003**, *68*, 9109–9112.

elution of CHCl₃ (200 mL) and CHCl₃/MeOH (98:2, 200 mL and then 95:5, 200 mL). The fraction eluted with CHCl₃/MeOH (95:5) was chromatographed successively by using a C₁₈ (CH₃CN/H₂O, 7:3) and then NH₂-SiO₂ columns (*n*-hexane/EtOAc, 2:1). A macrolide-containing fraction was separated by C₁₈ HPLC [YMC-Pack Pro C₁₈, 5 μm, YMC Co., Ltd., 10 × 250 mm; eluent, CH₃CN/H₂O (60:40); flow rate, 2 mL/min; UV detection at 210 nm] to afford iriomoteolide-3a (**1**, 2.3 mg, 0.015%).

Iriomoteolide-3a (1): colorless amorphous; [α]_D²⁵ +24 (*c* 0.18, CHCl₃); IR (neat) ν_{max} 3438 (broad), 2920 1707, and 1215 cm⁻¹; ¹H and ¹³C NMR data (Table 1); ESIMS (positive) *m/z* 457 (M + Na)⁺; ESIMS (negative) *m/z* 469 and 471 [ca. 3:1, (M + Cl)⁻]; HRESIMS *m/z* 457.2566 [calcd for C₂₅H₃₈O₆Na, (M + Na)⁺ 457.2566].

7,8-O-Isopropylidene Derivative (2) of Iriomoteolide-3a (1). To a solution of iriomoteolide-3a (**1**, 0.2 mg) in CH₂Cl₂ (20 μL) were added 2,2-dimethoxypropane (10 μL) and pyridinium *p*-toluenesulfonate (2 μg), and the mixture was stirred at 4 °C for 1 h. After evaporation of the solvent, the residue was subjected to a silica gel column (hexane/EtOAc, 8:1) to afford compound **2** (0.2 mg): ¹H NMR (CDCl₃) δ 1.01 (3H, d, *J* = 6.6 Hz, H₃-25), 1.05 (3H, d, *J* = 6.6 Hz, H₃-24), 1.28 (1H, m, H-16), 1.41 (1H, m, H-16), 1.42 (3H, s, H₃-26), 1.44 (3H, s, H₃-27), 1.57 (1H, m, H-13), 1.66 (3H, d, *J* = 6.6 Hz, H₃-23), 1.71 (1H, m, H-4), 1.86 (1H, m, H-3), 1.95 (1H, dd, *J* = 8.2 and 15.8 Hz, H-2), 2.22 (1H, br d, *J* = 14.0 Hz, H-13), 2.23 (1H, m, H-4), 2.37 (1H, m, H-17), 2.49 (1H, dd, *J* = 2.4 and 13.8 Hz, H-2), 2.67 (2H, m, H₂-20), 2.87 (1H, br d, *J* = 9.8 Hz, H-12), 3.06 (1H, dd, 2.3 and 9.8 Hz, H-11), 3.60 (1H, m, H-15), 3.93 (1H, t, *J* = 8.6 Hz, H-8), 4.02 (1H, t, *J* = 8.6 Hz, H-7), 5.17 (1H, m, H-14), 5.20 (1H, dd, 8.9 and 15.2 Hz, H-18), 5.32 (1H, dd, *J* = 9.8 and 15.2 Hz, H-10), 5.39–5.46 (3H, m, H-21, H-19, and H-22), 5.46 (1H, dd, *J* = 8.6 and 15.8 Hz, H-6), 5.82 (1H, ddd, *J* = 4.0, 10.0, and 15.8 Hz, H-5), and 5.60 (1H, dd, *J* = 8.6 and 15.2 Hz, H-9); ESIMS *m/z* 497.3 (M + Na)⁺; HRESIMS *m/z* 497.2883 [calcd for C₂₈H₄₂O₆Na (M + Na)⁺ 497.2879].

7,8,15-Tris-(S)-MTPA Ester (3a) of Iriomoteolide-3a (1). To a solution of iriomoteolide-3a (**1**, 0.2 mg) in 1% 4-dimethylaminopyridine (DMAP) solution in CH₂Cl₂ (20 μL) were added Et₃N (1 μL) and (R)-(-)-MTPACl (0.8 μL), and the mixture was stirred at 4 °C for 15 h. After addition of *N,N*-dimethyl-1,3-propanediamine (2 μL), the solvent was evaporated in vacuo. The residue was passed through a silica gel column (hexane/acetone, 8:1) to afford the 7,8,15-tris-(S)-MTPA ester (**3a**, 0.05 mg) of **1**: ¹H NMR (CDCl₃) δ

0.88 (3H, d, *J* = 6.6 Hz, H₃-25), 0.98 (3H, d, *J* = 6.6 Hz, H₃-24), 1.13 (1H, m, H-13b), 1.36 (1H, m, H-16b), 1.46 (1H, m, H-16a), 1.66 (3H, d, *J* = 6.6 Hz, H₃-23), 1.92 (1H, m, H-4b), 1.95 (1H, m, H-2b), 1.97 (1H, m, H-17), 2.20 (2H, m, H-2a and H-3), 2.22 (1H, m, H-13a), 2.39 (1H, m, H-4a), 2.62 (2H, s, H₂-20), 2.81 (1H, m, H-12), 2.83 (1H, m, H-11), 3.42 (3H, s), 3.45 (3H, s), 3.62 (3H, s), 5.09 (1H, dd, *J* = 8.5 and 15.5 Hz, H-18), 5.15 (1H, m, H-15), 5.25 (1H, m, H-6), 5.31 (1H, m, H-14), 5.34 (1H, m, H-19), 5.37–5.43 (2H, m, H-21 and H-22), 5.51 (2H, m, H-9 and H-10), 5.64 (1H, m, H-7), 5.70 (1H, m, H-8), 6.02 (1H, s, H-5), 7.35–7.42 (9H, m), and 7.50–7.58 (6H, m); ESIMS (positive) *m/z* 1105.4 (M + Na)⁺; HRESIMS *m/z* 1105.3728 [calcd for C₃₅H₅₀O₁₂F₉Na (M + Na)⁺ 1105.3761].

7,8,15-Tris-(R)-MTPA Ester (3b) of Iriomoteolide-3a (1). Iriomoteolide-3a (**1**, 0.2 mg) was treated with DMAP (20 μg), Et₃N (1 μL), and (S)-(+)-MTPACl (0.8 μL) by the same procedure as described above to afford the 7,8,15-tris-(R)-MTPA ester (**3b**, 0.12 mg) of **1**: ¹H NMR (CDCl₃) δ 0.96 (3H, d, *J* = 6.6 Hz, H₃-25), 0.98 (3H, d, *J* = 6.6 Hz, H₃-24), 1.10 (1H, m, H-13b), 1.44 (1H, m, H-16b), 1.55 (1H, m, H-16a), 1.66 (3H, d, *J* = 6.6 Hz, H₃-23), 1.92 (1H, m, H-4b), 1.95 (1H, m, H-2b), 2.03 (1H, m, H-17), 2.15 (1H, m, H-13a), 2.19 (1H, m, H-2a), 2.20 (1H, m, H-3), 2.44 (1H, m, H-4a), 2.62 (2H, s, H₂-20), 2.78 (1H, m, H-12), 2.82 (1H, m, H-11), 3.35 (3H, s), 3.40 (3H, s), 3.53 (3H, s), 5.15 (1H, dd, *J* = 8.5 and 15.5 Hz, H-18), 5.17 (1H, m, H-15), 5.25 (1H, m, H-14), 5.33 (1H, m, H-6), 5.37 (1H, m, H-19), 5.37–5.43 (2H, m, H-21 and H-22), 5.52 (1H, m, H-10), 5.67 (1H, m, H-8), 5.63 (2H, m, H-7 and H-9), 6.04 (1H, s, H-5), 7.35–7.42 (9H, m), and 7.50–7.58 (6H, m); ESIMS (positive) *m/z* 1105.4 (M + Na)⁺; HRESIMS *m/z* 1105.3772 [calcd for C₃₅H₅₀O₁₂F₉Na (M + Na)⁺ 1105.3761].

Acknowledgment. We thank Y. Endo, Y. Nagakita, and Y. Fukuda for help with dinoflagellate cultivation and S. Oka, Center for Instrumental Analysis, Hokkaido University, for ESIMS measurements. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Supporting Information Available: Spectral data for **1**, **2**, **3a**, and **3b**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JO702440S